As European markets show resilience, with the STOXX Europe 600 Index ending higher due to strong economic data and earnings results, investors are increasingly focusing on high-growth tech stocks that can capitalize on this positive momentum. In such an environment, a good stock might be characterized by its ability to innovate and adapt within the tech sector while leveraging favorable market conditions for sustained growth.
Top 10 High Growth Tech Companies In Europe
| Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
| Hacksaw |
28.53% |
33.50% |
★★★★★★ |
| Bonesupport Holding |
25.63% |
57.97% |
★★★★★★ |
| KebNi |
25.19% |
61.24% |
★★★★★★ |
| CD Projekt |
32.94% |
48.67% |
★★★★★★ |
| Pharma Mar |
16.39% |
34.00% |
★★★★★☆ |
| Kitron |
21.22% |
32.45% |
★★★★★★ |
| SyntheticMR |
18.81% |
47.40% |
★★★★★☆ |
| Comet Holding |
10.92% |
37.65% |
★★★★★☆ |
| Waystream Holding |
17.38% |
66.50% |
★★★★★☆ |
| Gapwaves |
29.76% |
59.76% |
★★★★★☆ |
Here we highlight a subset of our preferred stocks from the screener.
Datalogic
Simply Wall St Growth Rating:★★★★☆☆
Overview:Datalogic S.p.A. is a company that specializes in manufacturing and selling automatic data capture and process automation products across various regions including Italy, the Americas, Asia Pacific, Europe, the Middle East, and Africa with a market cap of €223.10 million.
Operations:Datalogic generates revenue primarily from its Data Capture segment, contributing €328.76 million, and its Industrial Automation segment, which adds €158.10 million.
Datalogic, navigating through a challenging fiscal period marked by a significant one-off loss of €6.2 million, still projects an optimistic earnings trajectory with an anticipated growth rate of 68.3% annually. Despite a slight dip in sales to €359.45 million from €366.36 million and net income falling to €1.18 million from €12.57 million year-over-year, the company's strategic focus on R&D and operational adjustments hint at robust future capabilities, especially as its revenue growth at 5.2% per year slightly outpaces the Italian market's 5.1%. This resilience in refining its core operations and investment in innovation may well position Datalogic for recovery and growth amidst evolving market demands.
Bonesupport Holding
Simply Wall St Growth Rating:★★★★★★
Overview:Bonesupport Holding AB (publ) is an orthobiologics company that specializes in developing and selling injectable bio-ceramic bone graft substitutes across Europe, North America, and other international markets, with a market cap of SEK13.24 billion.
Operations:Bonesupport generates revenue primarily from its pharmaceuticals segment, amounting to SEK1.12 billion. The company focuses on developing and selling injectable bio-ceramic bone graft substitutes in multiple regions, including Europe and North America.
Bonesupport Holding AB stands out in the European tech landscape, not just for its impressive revenue growth of 25.6% annually but also due to its strategic regulatory shifts that could redefine industry standards. Recently transitioning to a De Novo process with the FDA for its CERAMENT® V, this move could pioneer a new product category, echoing past successes with CERAMENT G. Moreover, with earnings expected to surge by 58% annually and robust returns on equity projected at 35.3%, Bonesupport is positioning itself as a formidable player in biotechnology innovations. This growth trajectory is further underscored by their latest guidance forecasting a sales increase of over 35%, signaling strong future prospects amidst evolving market conditions.
-
Unlock comprehensive insights into our analysis of Bonesupport Holding stock in this health report.
-
Understand Bonesupport Holding's track record by examining our Past report.
Sectra
Simply Wall St Growth Rating:★★★★☆☆
Overview:Sectra AB (publ) is a company that offers medical IT and cybersecurity solutions across Sweden, the United Kingdom, the Netherlands, and other parts of Europe, with a market capitalization of SEK43.27 billion.
Operations:Sectra generates revenue primarily from Imaging IT Solutions, contributing SEK2.95 billion, and Secure Communications, with SEK392.76 million. The company's focus on medical IT and cybersecurity solutions positions it in various European markets.
Sectra's recent strategic moves in the digital pathology and medical imaging sectors underscore its robust growth trajectory and innovation prowess. The company's foray into Japan with Matsunami Glass marks a significant expansion, enhancing diagnostic capabilities through digital pathology at Kameda Medical Center. Financially, Sectra demonstrated strong performance with Q2 revenues reaching SEK 903.48 million, a substantial increase from the previous year's SEK 779.4 million, complemented by a net income surge to SEK 148.4 million from SEK 87.76 million. This financial upturn is mirrored in its operational advancements like the Sectra One Cloud service for NHS trusts, which optimizes cybersecurity and IT management while fostering collaborative diagnostics across multiple sites—showcasing Sectra's commitment to integrating cutting-edge technology with client-centric solutions.
-
Click here and access our complete health analysis report to understand the dynamics of Sectra.
-
Gain insights into Sectra's past trends and performance with our Past report.
Taking Advantage
-
Investigate our full lineup of 45 European High Growth Tech and AI Stocks right here.
-
Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
-
Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Interested In Other Possibilities?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
-
Find companies with promising cash flow potential yet trading below their fair value .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BIT:DAL OM:BONEX and OM:SECT B.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
